ADVANTAGES
Technical Details:
Cyclin Dependant Kinase 2 (CDK2) is a member of a large family of protein kinases that initiates the principal transitions of the eukaryotic cell cycle. Mutations in the CDKs and/or their inhibitors are associated with several forms of cancer, making cyclin-dependent kinases important drug targets for cancer therapy. Tumor protein 53 (p53), is a transcription factor that regulates the cell cycle and thus functions as a tumor suppressor that is involved in preventing cancer.
Looking for Partners:
Commercial applications for these cell lines include use for validation studies of CDK2 inhibitors and the discovery of new anticancer therapeutics.
